Media stories about Retrophin (NASDAQ:RTRX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Retrophin earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.7645541037589 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Several research firms have recently issued reports on RTRX. BidaskClub raised shares of Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. ValuEngine raised shares of Retrophin from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. BMO Capital Markets dropped their price target on shares of Retrophin from $44.00 to $43.00 and set an “outperform” rating for the company in a research note on Wednesday, April 4th. Finally, Zacks Investment Research raised shares of Retrophin from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. Retrophin has an average rating of “Hold” and a consensus target price of $43.00.
RTRX stock opened at $26.65 on Friday. The firm has a market cap of $1,061.83, a PE ratio of -17.77 and a beta of 1.05. Retrophin has a 52-week low of $15.55 and a 52-week high of $28.25. The company has a quick ratio of 3.74, a current ratio of 3.80 and a debt-to-equity ratio of 0.15.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.20). Retrophin had a negative return on equity of 13.98% and a negative net margin of 38.55%. The firm had revenue of $42.18 million for the quarter, compared to the consensus estimate of $42.20 million. research analysts predict that Retrophin will post -1.6 EPS for the current year.
WARNING: “Retrophin (RTRX) Given Media Sentiment Rating of 0.18” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/22/retrophin-rtrx-given-media-sentiment-rating-of-0-18.html.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.